Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRC AML12 Trial for Acute Myeloid Leukemia
NCT00002658Phase 3Unknown
- Sponsor
- Medical Research Council
- Start
- Jan 1994
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone, tretinoin, filgrastim and cytarabine in acute myeloid leukemia (AML) (8 arms), sponsored by Medical Research Council. Primary endpoints: Remission Rate, Duration of Remission and 3 more. Status: unknown.
02
Drugs
mitoxantronetretinoinfilgrastimcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002658.